BSE · 544673
Modern Diagnostic & Research Centre Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹84 Cr with net profit ₹5 Cr — a 6.24% net margin, versus 11.43% the period before.
Shareholding
As of 2026-03-31
- Promoter72.85%
- Public11.64%
- FII0.03%
- DII15.48%
282 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.22× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Healthcare · ranked #1 of 85 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Apollo Hospitals Enter. Limited | ₹1,30,398 Cr | 61.98 | 13.75 | 20.48% | 7.91% |
| Max Healthcare Institute Ltd. | ₹1,03,161 Cr | 68.91 | 9.6 | 13.42% | 16.73% |
| Manipal Health Enterpri Limited | ₹1,00,094 Cr | 106.73 | 6.09 | 10.59% | 7.81% |
| Fortis Healthcare Ltd. | ₹67,493 Cr | 63.27 | 6.82 | 10.53% | 11.02% |
| Aster DM Quality Care Ltd. | ₹66,295 Cr | 170.91 | 15.76 | 8.48% | 6.54% |
| Global Health Limited | ₹40,226 Cr | 70.27 | 10.15 | 14.05% | 11.88% |
| Narayana Hrudayalaya Ltd. | ₹39,223 Cr | 45.5 | 8.64 | 17.76% | 9% |
| Krishna Institute of Medical Sciences Ltd. | ₹33,519 Cr | 160.57 | 8.94 | 10.74% | 4.85% |
| Dr. Lal Path Labs Ltd. | ₹32,299 Cr | 57.42 | 12.88 | 20.13% | 18.75% |
| Poly Medicure Ltd. | ₹17,504 Cr | 54.7 | 5.64 | 10.37% | 15.77% |
| Modern Diagnostic & Research Centre Ltd.(this company) | — | — | — | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashModern Diagnostic & Research Centre Ltd. has not specified its business activities. The company's 52-week high is Rs 100 and its 52-week low is Rs 49.
Positives
- +Revenue increased by 14.86% to Rs 78.8045 Cr in March 2025.
- +Net profit grew by 54.76% to Rs 8.9681 Cr in March 2025.
- +Promoter holding is high at 72.8514% as of March 31, 2026.
- +No promoter shares are pledged as of March 31, 2026.
Negatives
- −The debt-to-equity ratio is 1.31.
- −FII shareholding decreased to 0.0318% as of March 31, 2026, from 1.0703% as of January 31, 2026.
- −Public shareholding decreased to 11.6352% in March 2026 from 14.2737% in January 2026.
- −The number of shareholders decreased from 641 in January 2026 to 282 in March 2026.
Financial performance
The company's revenue increased by 14.86% to Rs 78.8045 Cr in March 2025, from Rs 68.672 Cr in March 2024. Net profit grew by 54.76% to Rs 8.9681 Cr in March 2025, compared to Rs 5.7948 Cr in March 2024. EBITDA also saw a growth of 68.76% to Rs 14.6319 Cr in March 2025 from Rs 8.6704 Cr in March 2024.
Profitability & returns
Modern Diagnostic & Research Centre Ltd. reported an earnings per share (EPS) of Rs 8.15 in March 2025, an increase from Rs 5.27 in March 2024. This follows a period of negative EPS, with -Rs 5.21 in March 2023 and -Rs 1.32 in March 2022.
Balance sheet
The company has a debt-to-equity ratio of 1.31.
Ownership & pledges
As of March 31, 2026, promoters held 72.8514% of the company. Institutional investors, including DIIs and FIIs, collectively held 15.5134% of the shares. Public shareholding was 11.6352%. There were no promoter shares pledged as of March 31, 2026.
Regulatory & surveillance
No information regarding surveillance measures for Modern Diagnostic & Research Centre Ltd. was available in the provided data.
Data as of — price: 2026-09-23 · financials: Mar 26 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Modern Diagnostic & Research Centre Ltd.share price & fundamentals